Condition
Thalidomide
Total Trials
5
Recruiting
2
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 2 (2)
P 3 (1)
P 4 (1)
Trial Status
Recruiting2
Unknown2
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06268093Phase 2Recruiting
The Therapeutic Effect of Thalidomide in Syringomyelia
NCT06256627Not ApplicableRecruiting
The Maintenance Treatment of "ITIVA" in AML Patients
NCT05525234Phase 4Unknown
A Study of Thalidomide in the Treatment of Refractory Uremic Pruritus
NCT03318835Phase 3UnknownPrimary
Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients
NCT00964496Phase 2Completed
Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation
Showing all 5 trials